These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Low glomerular density is a risk factor for progression in idiopathic membranous nephropathy. Tsuboi N, Kawamura T, Miyazaki Y, Utsunomiya Y, Hosoya T. Nephrol Dial Transplant; 2011 Nov; 26(11):3555-60. PubMed ID: 21771759 [Abstract] [Full Text] [Related]
7. [Factors in the progression of renal insufficiency during the 2 years preceding the use of dialysis]. Kacso I, Gherman M, Mazouz H, Ghazali A, el Esper N, Morinière P, Makdassi R, Hardy P, Westeel PF, Achard JM, Pruna A, Fournier A. Nephrologie; 1999 Nov; 20(1):19-28. PubMed ID: 10081033 [Abstract] [Full Text] [Related]
8. [The late results of treating membranous glomerulonephritis]. Belovezhdov N, Robeva R, Dimitrova V. Vutr Boles; 1990 Nov; 29(3):53-60. PubMed ID: 2284800 [Abstract] [Full Text] [Related]
11. Hydrocarbon exposure and tubular damage: additional factors in the progression of renal failure in primary glomerulonephritis. Yaqoob M, Stevenson A, Mason H, Bell GM. Q J Med; 1993 Oct; 86(10):661-7. PubMed ID: 8255964 [Abstract] [Full Text] [Related]
12. Renal pathology in idiopathic membranous nephropathy: a new perspective. Troyanov S, Roasio L, Pandes M, Herzenberg AM, Cattran DC. Kidney Int; 2006 May; 69(9):1641-8. PubMed ID: 16572119 [Abstract] [Full Text] [Related]
14. Clinical and morphological prognostic factors in membranous nephropathy: significance of focal segmental glomerulosclerosis. Dumoulin A, Hill GS, Montseny JJ, Meyrier A. Am J Kidney Dis; 2003 Jan; 41(1):38-48. PubMed ID: 12500220 [Abstract] [Full Text] [Related]
15. Short- and long-term efficacy of oral cyclophosphamide and steroids in patients with membranous nephropathy and renal insufficiency. Study Group. Branten AJ, Wetzels JF. Clin Nephrol; 2001 Jul; 56(1):1-9. PubMed ID: 11499653 [Abstract] [Full Text] [Related]
16. Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate. du Buf-Vereijken PW, Branten AJ, Wetzels JF, Membranous Nephropathy Study Group. Nephrol Dial Transplant; 2004 May; 19(5):1142-8. PubMed ID: 14993502 [Abstract] [Full Text] [Related]
17. Idiopathic membranous nephropathy in pediatric patients: presentation, response to therapy, and long-term outcome. Chen A, Frank R, Vento S, Crosby V, Chandra M, Gauthier B, Valderrama E, Trachtman H. BMC Nephrol; 2007 Aug 06; 8():11. PubMed ID: 17683621 [Abstract] [Full Text] [Related]
18. Spontaneous remission of nephrotic syndrome in membranous nephropathy with chronic renal impairment. Polanco N, Gutiérrez E, Rivera F, Castellanos I, Baltar J, Lorenzo D, Praga M, Grupo de Estudio de las Enfermedades Glomerulares de la Sociedad Española de Nefrología (GLOSEN). Nephrol Dial Transplant; 2012 Jan 06; 27(1):231-4. PubMed ID: 21624942 [Abstract] [Full Text] [Related]
19. Idiopathic membranous nephropathy in the elderly: a comparative study. Zent R, Nagai R, Cattran DC. Am J Kidney Dis; 1997 Feb 06; 29(2):200-6. PubMed ID: 9016890 [Abstract] [Full Text] [Related]
20. Treatment of renal failure in idiopathic membranous nephropathy with azathioprine and prednisolone. Brown JH, Douglas AF, Murphy BG, Hill CM, McNamee PT, Nelson WE, Doherty CC. Nephrol Dial Transplant; 1998 Feb 06; 13(2):443-8. PubMed ID: 9509460 [Abstract] [Full Text] [Related] Page: [Next] [New Search]